B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy             for the treatment of malignant ascites.
To minimize invasive surgery, we employed B ultrasound to guide the placement             of the catheters used in continuous circulatory hyperthermic intraperitoneal perfusion             chemotherapy (CHIPC) in malignant ascites treatment. Thirty-two patients with             malignant ascites were treated with CHIPC guided by B-mode ultrasound. Ascites             were originally from ovarian cancer (11 cases), gastric cancer (10 cases), colorectal             cancer (9 cases) and pancreatic cancer (2 cases). The CHIPC was carried out at             43˚C for 90 min with 0.9% saline solution as a carrier containing cisplatin and             doxorubicin or mitomycin-C as therapeutic reagents depending on the type of the             primary tumor. The therapeutic efficacy, postoperative complications and survival             period of these patients were assessed with follow-up examinations. Among all             participates to be assessed with ascites, 26 and 4 patients showed complete remission             (CR) and partial remission (PR) respectively, with an objective remission rate             (ORR) of 93.75%. The KPS scores were elevated by 23.1±9.0 after 3 sessions of             ultrasound guided CHIPC and the quality of life (QOF) of patients was significantly             improved (p<0.01). The median survival time was 9 months and 18 patients survived             between 3 and 30 months after CHIPC treatment. Additionally, patients with different             types of cancers significantly differed in the survival time (p<0.01). A novel             approach of using B ultrasound guided CHIPC for the treatment of malignant ascites             demonstrated satisfactory outcomes. The approach shows benefit in minimizing invasive             surgery, improving the patient QOF and prolonging survival time.
The Institute of Anatomy, School of Basic Medical Sciences, Southern Medical University, and Intracelom Hyperthermic Perfusion Therapy Center, Cancer Hospital of Guangzhou Medical College, Guangzhou 510515, PR China.
Shuzhong
S
Cui
Mingchen
M
Ba
Yunqiang
Y
Tang
Jifang
J
Liu
Yinbing
Y
Wu
Bin
B
Wang
Xiangliang
X
Zhang
Hongsheng
H
Tang
Shizhen
S
Zhong
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001201:Ascites / Q000188:drug therapy* / Q000209:etiology; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional / Q000379:methods
D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin